Online inquiry

IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5774MR)

This product GTTS-WQ5774MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5774MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2426MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ14700MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ1769MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ15600MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ3250MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ10501MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ14099MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ14618MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC0001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW